Weave Bio has secured $10 million in funding to accelerate its mission of streamlining regulatory processes for pharma and biotech. Its AI-powered platform, starting with AutoIND, automates and accelerates the IND submission process, reducing preparation time by over 50% and potentially bringing new therapies to patients faster while lowering development costs.
Press release
Weave Bio AI secures $10 million in funding
Related news
Press release
Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
Press release
Two Former FDA Leaders Join Weave Bio’s Strategic Advisory Board
Press release
Weave Bio Enables Global Submissions
News